Global prediabetes market is anticipated to grow at a CAGR of 7.2% during the forecast period (2024-2031). A major factor supporting the growth of the market is the increasing product expansion and new drugs in the market. For instance, in January 2024, Novo Nordisk announced the launch of its Wegovy, a GLP-1 analog in the UK. This drug can be prescribed to people with prediabetes and for weight loss purposes. Similarly, some of the other product launches include-
Browse the full report description of “Prediabetes Market Size, Share & Trends Analysis Report by Drug Class (Diguanide, Thiazolidinediones (TZDs), Glucagon-like Peptide-1 Agonists (GLP-1), SGLT2 Inhibitors, DPP-4 Inhibitors, and Others), and by Age Group (Children, Adult, and Elderly) Forecast Period (2024-2031)” at https://www.omrglobal.com/industry-reports/prediabetes-market
- In November 2023, Valbiotis, a commercially oriented R&D company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases (CVDs), announced the successful completion of the mode of action clinical study on TOTUM•63, against prediabetes and the early stages of Type 2 diabetes.
- In April 2023, PharmaLinea launched Prediabetiq capsules, a clinically supported private-label food supplement that aims to reduce post-meal blood glucose levels and improve insulin efficacy and sensitivity. According to PharmaLinea, the product’s key active ingredient Qgluco, reduced mean blood glucose by 45% 60 minutes after a meal when compared to a placebo. The company expects the market for diabetes and prediabetes supplements to grow due to increasing diabetes rates, consumer awareness of glucose control, and increased use of continuous blood glucose monitors.
- In April 2023, Nestlé USA launched a new line of ready meals for people managing their blood sugar levels, building on similar launches in Malaysia and China -and products that help control blood sugar levels are in trend. It launched under its Lean Cuisine brand, the Balance Bowls range which contains four stock-keeping units (SKUs): Tex-Mex Rice and Black Beans; Lemon Garlic Shrimp Stir-Fry; Roasted Eggplant Parmesan Pasta; and Creamy Pasta Primavera.
Market Coverage
• The market number available for – 2023-2031
• Base year- 2023
• Forecast period- 2024-2031
• Segment Covered-
o By Drug Class
o By Age Group
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- includes Novo Nordisk A/S, Valbiotis, Resverlogix Corp., Aphaia Pharma, AstraZeneca, Bristol-Myers Squibb, and Boehringer Ingelheim International GmbH, among others.
Key questions addressed by the report.
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Prediabetes Market Report Segment
By Drug Class
- Diguanide
- Thiazolidinediones (TZDS)
- Glucagon-like Peptide-1 Agonists (GLP-1)
- SGLT2 Inhibitors
- DPP-4 Inhibitors
- Others (Glucagon-like peptide 1 (GLP-1), Sulfonylureas)
By Age Group
- Children (12 to 18 Years)
- Adult (18 to 50 Years)
- Elderly (Above 50 Years)
Global Prediabetes Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• The Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/prediabetes-market